CN102984941B - 用于治疗白血病的组合物和方法 - Google Patents

用于治疗白血病的组合物和方法 Download PDF

Info

Publication number
CN102984941B
CN102984941B CN201080050708.8A CN201080050708A CN102984941B CN 102984941 B CN102984941 B CN 102984941B CN 201080050708 A CN201080050708 A CN 201080050708A CN 102984941 B CN102984941 B CN 102984941B
Authority
CN
China
Prior art keywords
compound
mll
compounds
multiple endocrine
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080050708.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102984941A (zh
Inventor
J·赫斯
J·格雷姆贝卡
T·切尔皮基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Michigan System
Original Assignee
University of Michigan System
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Virginia Patent Foundation filed Critical University of Michigan System
Publication of CN102984941A publication Critical patent/CN102984941A/zh
Application granted granted Critical
Publication of CN102984941B publication Critical patent/CN102984941B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201080050708.8A 2009-09-04 2010-09-03 用于治疗白血病的组合物和方法 Active CN102984941B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24010209P 2009-09-04 2009-09-04
US61/240102 2009-09-04
PCT/US2010/047894 WO2011029054A1 (en) 2009-09-04 2010-09-03 Compositions and methods for treatment of leukemia

Publications (2)

Publication Number Publication Date
CN102984941A CN102984941A (zh) 2013-03-20
CN102984941B true CN102984941B (zh) 2016-08-17

Family

ID=43649670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080050708.8A Active CN102984941B (zh) 2009-09-04 2010-09-03 用于治疗白血病的组合物和方法

Country Status (7)

Country Link
US (2) US8993552B2 (https=)
EP (1) EP2473054B1 (https=)
JP (2) JP5792171B2 (https=)
CN (1) CN102984941B (https=)
AU (2) AU2010289321A1 (https=)
CA (1) CA2773131C (https=)
WO (1) WO2011029054A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EA021113B1 (ru) 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
WO2012097013A1 (en) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
WO2013068592A1 (en) * 2011-11-10 2013-05-16 Fondation Jerome Lejeune Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
EP2806875B1 (en) * 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2671575A1 (en) * 2012-06-04 2013-12-11 Universität Regensburg Ras inhibitors
LT2858987T (lt) 2012-06-11 2018-07-10 Bristol-Myers Squibb Company Fosforamido rūgšties provaistai iš 5-[5-fenil-4-(piridin-2-ilmetilamino)chinazolin-2-il]piridin-3-sulfonamido
WO2014011906A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102215272B1 (ko) * 2012-09-28 2021-02-15 이그니타, 인코포레이티드 비정형 단백질 키나제 c의 아자퀴나졸린 억제제
GB201217704D0 (en) * 2012-10-03 2012-11-14 Ucb Pharma Sa Therapeutic agents
US20140136295A1 (en) 2012-11-13 2014-05-15 Apptio, Inc. Dynamic recommendations taken over time for reservations of information technology resources
CA2890911A1 (en) 2013-01-10 2014-07-17 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014127191A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of Michigan Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
CN104119343A (zh) * 2013-04-25 2014-10-29 苏州科捷生物医药有限公司 2-三氟甲基噻二唑类化合物及其用途
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
TWI648281B (zh) * 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
EP3116867A4 (en) * 2014-03-11 2017-10-18 Godavari Biorefineries Ltd. Cancer stem cell targeting compounds
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CN104592248A (zh) * 2014-12-31 2015-05-06 芜湖杨燕制药有限公司 一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
TWI703150B (zh) * 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) * 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EP3512857B1 (en) * 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
CA3033020A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
CN110248946B (zh) * 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
MX2019011412A (es) 2017-03-31 2020-02-07 Univ Michigan Regents Piperidinas como inhibidores de menina covalentes.
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
EP3810145A4 (en) 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
CA3112340A1 (en) 2018-10-03 2020-04-09 The Regents Of The University Of Michigan Small molecule menin inhibitors
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
WO2021063346A1 (zh) * 2019-09-30 2021-04-08 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2022086937A1 (en) * 2020-10-21 2022-04-28 Icahn School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of enl
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
US20240417405A1 (en) 2021-05-08 2024-12-19 Janssen Pharmaceutica Nv Substituted Spiro Derivatives
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
WO2022262796A1 (en) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305479A (zh) * 1998-06-19 2001-07-25 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
CN101242838A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 用氨基喹啉和氨基喹唑啉激酶调节剂协同调节flt3激酶
CN101242846A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 使用噻吩并嘧啶类和噻吩并吡啶类激酶调节剂的flt3激酶协同调制
CN101466716A (zh) * 2006-04-07 2009-06-24 德维洛根股份公司 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10330377A (ja) * 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
MXPA03009925A (es) * 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
WO2004030672A1 (en) 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
AU2003258662A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
EP1663962A4 (en) * 2003-08-22 2007-08-22 Dendreon Corp COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION
US20050123906A1 (en) 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation
US20060025406A1 (en) 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
TW200800225A (en) 2005-09-02 2008-01-01 Tibotec Pharm Ltd Benzodiazepines as HCV inhibitors
WO2008099019A1 (en) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors
FR2913017A1 (fr) 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
JP5284291B2 (ja) 2007-03-19 2013-09-11 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 潜在的制癌剤としての新規アントラニル酸誘導体及びその調製方法
CA2687187A1 (en) 2007-05-25 2008-12-18 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
WO2009064388A2 (en) 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
CN102186479A (zh) * 2008-09-10 2011-09-14 凯利普西斯公司 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
WO2011003418A1 (en) 2009-07-08 2011-01-13 Leo Pharma A/S Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305479A (zh) * 1998-06-19 2001-07-25 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
CN101242838A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 用氨基喹啉和氨基喹唑啉激酶调节剂协同调节flt3激酶
CN101242846A (zh) * 2005-06-10 2008-08-13 詹森药业有限公司 使用噻吩并嘧啶类和噻吩并吡啶类激酶调节剂的flt3激酶协同调制
CN101466716A (zh) * 2006-04-07 2009-06-24 德维洛根股份公司 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用

Also Published As

Publication number Publication date
CA2773131A1 (en) 2011-03-10
AU2014203516B2 (en) 2016-06-09
JP2013503906A (ja) 2013-02-04
US20160045504A1 (en) 2016-02-18
CN102984941A (zh) 2013-03-20
AU2014203516A1 (en) 2014-07-17
EP2473054B1 (en) 2017-06-14
CA2773131C (en) 2015-07-14
EP2473054A4 (en) 2013-05-01
EP2473054A1 (en) 2012-07-11
JP5792171B2 (ja) 2015-10-07
AU2010289321A1 (en) 2012-04-05
US20110065690A1 (en) 2011-03-17
WO2011029054A1 (en) 2011-03-10
JP2015143283A (ja) 2015-08-06
US8993552B2 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
CN102984941B (zh) 用于治疗白血病的组合物和方法
Banerji et al. Synthesis of triazole-substituted quinazoline hybrids for anticancer activity and a lead compound as the EGFR blocker and ROS inducer agent
JP5677296B2 (ja) グリオーマの治療のためのｃｄｋ阻害剤の使用
Pan et al. Targeting bromodomain-containing proteins: research advances of drug discovery
JP2021525224A (ja) Ｂｃｌ−２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用
JP2016520130A (ja) 心臓疾患における新規治療戦略としてのｂｅｔ阻害
Yang et al. Novel benzo five-membered heterocycle derivatives as P-glycoprotein inhibitors: design, synthesis, molecular docking, and anti-multidrug resistance activity
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
Zhu et al. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy
El‐Gamil et al. Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights
Wang et al. Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non–small cell lung cancer
Bharathiraja et al. Solasodine targets NF-κB signaling to overcome P-glycoprotein mediated multidrug resistance in cancer
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
JP7353663B2 (ja) Ｇａｂａａ受容体リガンド
AU2020320289B2 (en) Anticancer agents
JP2009521484A (ja) ３−アリール置換キナゾロンおよびその使用
JP2023528945A (ja) Ｆｒｓ２－ｆｇｆｒ相互作用の小分子阻害剤、並びに医薬における、がんの予防及び治療における、その使用
JP6748704B2 (ja) 抗癌治療剤
WO2023105008A1 (en) Small-molecule inhibitors of the frs2-fgfr interaction
JP2023552368A (ja) Ｙボックス結合タンパク質１阻害剤
Zhang et al. Discovery of Potent and Selective Pyrrolo [2, 3-d] Pyrimidine-Based Aurora A Inhibitors with Demonstrated Efficacy against Patient-Derived Gastric Cancer Organoids
Han et al. Pharmacological activation of the p53 pathway by a new compound CYZ2017 exerts anti-tumor effects
Yang et al. Fluzoparib: the first Chinese original poly (ADP-ribose) polymerase inhibitor for the treatment of BRCA1/2 mutated ovarian cancer
Nakao et al. Effect of anticancer activity of aripiprazole main metabolite OPC-14857 on malignant glioblastoma
Atlas Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant